What was the market valuation of the UK multiplex assays market in 2024?

The market valuation was $193.64 Million in 2024. Read More

What is the projected market valuation for the UK multiplex assays market by 2035?

The projected valuation for 2035 is $394.79 Million. Read More

What is the expected CAGR for the UK multiplex assays market during the forecast period 2025 - 2035?

The expected CAGR is 6.69% during the forecast period 2025 - 2035. Read More

Which application segment had the highest valuation in the UK multiplex assays market in 2024?

The Clinical Diagnostics segment had the highest valuation, ranging from $60.0 Million to $120.0 Million. Read More

What technology segment is projected to grow significantly in the UK multiplex assays market?

The ELISA (Enzyme-Linked Immunosorbent Assay) technology segment is projected to grow, with valuations between $78.64 Million and $164.79 Million. Read More

Which end user segment contributed the most to the UK multiplex assays market in 2024?

Pharmaceutical Companies contributed the most, with valuations between $72.0 Million and $151.79 Million. Read More

What are the key players in the UK multiplex assays market?

Key players include Thermo Fisher Scientific, Abbott Laboratories, Roche Diagnostics, and others. Read More

What platform segment is expected to show strong performance in the UK multiplex assays market?

The Nucleic Acid Platforms segment is expected to show strong performance, with valuations between $60.0 Million and $120.0 Million. Read More

How does the market for Drug Discovery compare to other application segments in 2024?

The Drug Discovery segment had a valuation ranging from $40.0 Million to $80.0 Million, indicating a moderate position compared to others. Read More

What is the valuation range for the Flow Cytometry technology segment in the UK multiplex assays market?

The valuation range for the Flow Cytometry technology segment is between $20.0 Million and $40.0 Million. Read More

UK Multiplex Assays Market

UK Multiplex Assays Market Research Report By Application (Clinical Diagnostics, Drug Discovery, Environmental Testing, Food Safety Testing, Genetic Research), By Technology (Luminex xMAP Technology, Magnetic Bead-Based Assays, Flow Cytometry, PCR, ELISA), By Platform (Microarray Platforms, Nucleic Acid Platforms, Protein Platforms, Cell-Based Platforms) and By End User (Hospitals, Laboratories, Research Institutions, Pharmaceutical Companies) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

6.69%

2024 Market Size

$ 193.64 Million

2035 Market Size

$ 394.79 Million

Healthcare ● Updated February 2026 Report ID: MRFR/HC/51927-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Pharmaceutical, BY Application (USD Million)
  1. 4.1.1 Clinical Diagnostics
  2. 4.1.2 Drug Discovery
  3. 4.1.3 Environmental Testing
  4. 4.1.4 Food Safety Testing
  5. 4.1.5 Genetic Research
2. 4.2 Pharmaceutical, BY Technology (USD Million)
  1. 4.2.1 Luminex xMAP Technology
  2. 4.2.2 Magnetic Bead-Based Assays
  3. 4.2.3 Flow Cytometry
  4. 4.2.4 PCR (Polymerase Chain Reaction)
  5. 4.2.5 ELISA (Enzyme-Linked Immunosorbent Assay)
3. 4.3 Pharmaceutical, BY Platform (USD Million)
  1. 4.3.1 Microarray Platforms
  2. 4.3.2 Nucleic Acid Platforms
  3. 4.3.3 Protein Platforms
  4. 4.3.4 Cell-Based Platforms
4. 4.4 Pharmaceutical, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Laboratories
  3. 4.4.3 Research Institutions
  4. 4.4.4 Pharmaceutical Companies
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Pharmaceutical
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Thermo Fisher Scientific (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Abbott Laboratories (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Roche Diagnostics (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Agilent Technologies (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Bio-Rad Laboratories (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck KGaA (DE)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 PerkinElmer (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Luminex Corporation (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Qiagen N.V. (NL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 UK MARKET ANALYSIS BY APPLICATION
3. 6.3 UK MARKET ANALYSIS BY TECHNOLOGY
4. 6.4 UK MARKET ANALYSIS BY PLATFORM
5. 6.5 UK MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF PHARMACEUTICAL
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF PHARMACEUTICAL
9. 6.9 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
10. 6.10 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
11. 6.11 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
13. 6.13 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
14. 6.14 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
15. 6.15 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
16. 6.16 PHARMACEUTICAL, BY PLATFORM, 2024 (% SHARE)
17. 6.17 PHARMACEUTICAL, BY PLATFORM, 2024 TO 2035 (USD Million)
18. 6.18 PHARMACEUTICAL, BY END USER, 2024 (% SHARE)
19. 6.19 PHARMACEUTICAL, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Million)
  3. 7.2.3 BY PLATFORM, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

UK Multiplex Assays Market Segmentation

UK Multiplex Assays Market By Application (USD Million, 2025-2035)

Clinical Diagnostics
Drug Discovery
Environmental Testing
Food Safety Testing
Genetic Research

UK Multiplex Assays Market By Technology (USD Million, 2025-2035)

Luminex xMAP Technology
Magnetic Bead-Based Assays
Flow Cytometry
PCR (Polymerase Chain Reaction)
ELISA (Enzyme-Linked Immunosorbent Assay)

UK Multiplex Assays Market By Platform (USD Million, 2025-2035)

Microarray Platforms
Nucleic Acid Platforms
Protein Platforms
Cell-Based Platforms

UK Multiplex Assays Market By End User (USD Million, 2025-2035)

Hospitals
Laboratories
Research Institutions
UK Multiplex Assays Market Companies

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”